1. Home
  2. KRYS vs ORA Comparison

KRYS vs ORA Comparison

Compare KRYS & ORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • ORA
  • Stock Information
  • Founded
  • KRYS 2015
  • ORA 1965
  • Country
  • KRYS United States
  • ORA United States
  • Employees
  • KRYS N/A
  • ORA N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • ORA Electric Utilities: Central
  • Sector
  • KRYS Health Care
  • ORA Utilities
  • Exchange
  • KRYS Nasdaq
  • ORA Nasdaq
  • Market Cap
  • KRYS 4.3B
  • ORA 4.6B
  • IPO Year
  • KRYS 2017
  • ORA 2004
  • Fundamental
  • Price
  • KRYS $152.08
  • ORA $88.15
  • Analyst Decision
  • KRYS Strong Buy
  • ORA Buy
  • Analyst Count
  • KRYS 11
  • ORA 8
  • Target Price
  • KRYS $204.27
  • ORA $88.75
  • AVG Volume (30 Days)
  • KRYS 273.6K
  • ORA 473.5K
  • Earning Date
  • KRYS 08-04-2025
  • ORA 08-06-2025
  • Dividend Yield
  • KRYS N/A
  • ORA 0.55%
  • EPS Growth
  • KRYS 109.01
  • ORA N/A
  • EPS
  • KRYS 4.16
  • ORA 2.06
  • Revenue
  • KRYS $333,448,000.00
  • ORA $885,250,000.00
  • Revenue This Year
  • KRYS $40.10
  • ORA $9.65
  • Revenue Next Year
  • KRYS $49.73
  • ORA $14.25
  • P/E Ratio
  • KRYS $36.60
  • ORA $42.63
  • Revenue Growth
  • KRYS 247.53
  • ORA 1.95
  • 52 Week Low
  • KRYS $122.80
  • ORA $61.58
  • 52 Week High
  • KRYS $213.52
  • ORA $91.81
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 58.86
  • ORA 57.67
  • Support Level
  • KRYS $147.35
  • ORA $88.90
  • Resistance Level
  • KRYS $154.99
  • ORA $91.81
  • Average True Range (ATR)
  • KRYS 4.29
  • ORA 1.23
  • MACD
  • KRYS 0.08
  • ORA -0.41
  • Stochastic Oscillator
  • KRYS 66.32
  • ORA 37.22

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About ORA Ormat Technologies Inc.

Ormat Technologies Inc is engaged in the geothermal and recovered energy power business. It is engaged in three business segments: Electricity Segment. where the company develops, builds, owns and operates geothermal, solar PV and recovered energy-based power plants in the United States and geothermal power plants in other countries and sell the electricity generated. Product Segment includes designing, manufacturing and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement and construction of geothermal and recovered energy-based power plants. Energy Storage Segment includes owning and operating grid-connected which provide capacity, energy and ancillary services directly to the electric grid.

Share on Social Networks: